Stockreport

BridgeBio Pharma: Genetic Disease Specialist Is Thriving - I'm Upgrading To Buy [Seeking Alpha]

BridgeBio Pharma, Inc.  (BBIO) 
Last bridgebio pharma, inc. earnings: 3/2 08:29 am Check Earnings Report
PDF Attruby posted $362m in 2025 sales but faces stiff competition from Pfizer and Alnylam, with future generic threats and no 2026 revenue guidance provided. BBIO report [Read more]